<DOC>
	<DOCNO>NCT03019055</DOCNO>
	<brief_summary>This phase 1 , interventional single arm , open label , treatment study design evaluate safety feasibility infusion autologous T cell engineer contain anti-CD19 anti-CD20 scFv couple CD3ζ 4-1BB signaling domains patient relapse and/or refractory CD19 CD20 positive B cell malignancy</brief_summary>
	<brief_title>Study CAR-20/19-T Cells Patients With Relapsed Refractory B Cell Malignancies</brief_title>
	<detailed_description>This single center , single arm , open label phase I study demonstrate feasibility manufacture CAR-T cell express tandem receptor CD20 CD19 ( CAR-20/19-T ) completely close system use CliniMACS Prodigy device determine safety dual targeted CAR first-in-human study patient relapse refractory B cell malignancy . Secondary outcome include response rate , observed toxicity treatment , specifically development cytokine release syndrome ( CRS ) , inflammatory storm see previous CAR-T therapy .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients age ≥1 year ≤65 year CD19 CD20 positive B cell malignancy CLL/SLL , B cell NHL , ALL active disease available curative option meet clinical criterion initiate treatment . 2 . Patients NHL , CLL/SLL , ALL must CD19 CD20 positive disease recent biopsy perform 3 . Absolute CD3+ T cell count ≥100/mm3 . Patients receive chemotherapy and/or steroid CD3+ Tcell count , apheresis , require test repeat . 4 . Lumbar puncture CSF analysis cytology flow cytometry patient ALL patient prior history CNS disease . For patient NHL CLL without history CNS positive disease , negative MRI brain suffice . 5 . MRI brain without evidence CNS involvement 6 . Measurable disease must document within 4 week time consent define follow disease specific subtype : 1 . NHL : Patients active disease define nodal lesion great 20 mm long axis extranodal lesion &gt; 10 mm long short axis bone marrow involvement biopsy proven 2 . ALL : At minimum patient need minimal residual disease detectable flow cytometry bone marrow peripheral blood . 3 . CLL : Active disease either bone marrow , peripheral flow cytometry , CT and/or PET image nodal disease 7 . Patients fail least one line standard treatment meet disease specific criterion detail : 1 . CLL : measurable disease peripheral flow cytometry , bone marrow biopsy , CT image relapse least one line chemo immunotherapy progress ibrutinib monotherapy 2 . B cell ALL : must receive least one induction regimen active disease . 3 . B cell NHL ( CD19 CD20 ) positive B cell NHL include limited Follicular lymphoma , Diffuse Large B cell Lymphoma ( de novo transform ) , Mantle cell lymphoma , Marginal zone lymphoma , Waldenstrom 's macroglobulinemia , Prolymphocytic lymphoma : Must progress Rituximab another CD20 antibody chemotherapy regimen appropriate disease . 8 . Karnofsky performance score ≥70 pts age≥16 Lansky score ≥70 pt age &lt; 16 9 . Adequate hepatic function , define AST ALT &lt; 3 x upper limit normal ( ULN ) ; serum bilirubin alkaline phosphatase &lt; 2 x ULN , consider clinically significant ( e.g Gilbert 's indirect hyperbilirubinemia ) felt due underlying disease . 10 . Adequate renal function , define serum creatinine &lt; 2 x ULN . 11 . Able provide write informed consent , agree practice birth control study . 12 . Adequate cardiac function indicate New York Heart Association ( NYHA ) classification I II AND leave ventricular ejection fraction ≥40 % ( cardiac ECHO MUGA ) adequate pulmonary function indicate room air oxygen saturation ≥92 % . 13 . Expected survival &gt; 12 week 14 . Negative urine serum pregnancy test females child bear potential study entry within 48 hour ' prior lymphodepleting chemotherapy . 15 . Patients prior blinatumomab treatment require repeat biopsy postblinatumomab treatment demonstrate CD19 CD20 positive disease . 16 . Meet criterion regard fertility contraception detail Special Criteria regard Fertility Contraception ( ) . Exclusion Criteria A potential subject meet follow exclusion criterion ineligible participate study . 1 . Positive betaHCG female childbearing potential . 2 . Patients know systemic allergy bovine murine product . 3 . Known prior positive serology human antimouse antibody ( HAMA ) . 4 . Confirmed active human immunodeficiency virus ( HIV ) , Hepatitis B C infection . 5 . History significant autoimmune disease OR active , uncontrolled autoimmune phenomenon : systemic lupus erythematous , wegner 's glomerulonephritis , autoimmune hemolytic anemia , idiopathic thrombocytopenic purpura ( AIHA , ITP ) require steroid therapy define &gt; 20 mg prednisone equivalent daily adult &gt; 0.25 mg/kg prednisone equivalent daily child ( except patient physiologic dos replacement steroid ) 6 . Presence ≥grade 3 nonhematologic toxicity per CTCAE version 4.03 previous treatment unless felt due underlying disease . 7 . Concurrent use investigational therapeutic agent enrollment another therapeutic clinical trial institution 8 . Refusal participate longterm followup protocol 9 . Patients active CNS involvement malignancy MRI lumbar puncture ( CNS2 CNS3 disease ) . Patients prior CNS disease effectively treat eligible provide treatment &gt; 4 week enrollment remission document within 6 week plan CART cell infusion 10 . Previous recipient allogeneic hematopoietic stem cell transplantation ( AHCT ) exclude &lt; 100 day ' posttransplant , evidence active graftversushostdisease ( GVHD ) grade , currently immunosuppression . 11 . Previous CART cell therapy direct either CD19 CD20 12 . AntiCD20 antibody treatment within 4 week cell infusion 13 . AntiCD19 antibody treatment within 4 week cell infusion 14 . Chemotherapy lymphodepletion within 2 week infusion 15 . Cytotoxic chemotherapy treatment within 21 day steroid treatment ( replacement dose steroid ) within 7 day prior apheresis collection CART cell 16 . Patients post solid organ transplant develop high grade lymphoma leukemias 17 . Concurrent active malignancy ( exception : treat solid malignancy &gt; 5 year ' remission , treat basal squamous cell carcinoma skin ) Special Criteria regard Fertility Contraception Female subject reproductive potential ( woman reach menarche woman postmenopausal least 24 consecutive month , i.e. , menses within precede 24 month , undergone sterilization procedure [ hysterectomy bilateral oophorectomy ] ) must negative serum urine pregnancy test perform part eligibility criterion within 48 hour initiation lymphodepleting chemotherapy . Due highrisk level study , enrol , subject must agree participate conception process ( e.g. , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) . Additionally , participate sexual activity could lead pregnancy , study subject must agree use reliable double barrier method contraception followup period protocol . Acceptable birth control include combination two follow method : Condoms* ( male female ) without spermicidal agent . Diaphragm cervical cap spermicide Intrauterine device ( IUD ) Hormonalbased contraception Subjects reproductive potential ( woman premenarche postmenopausal least 24 consecutive month undergone hysterectomy tubal ligation , salpingectomy , and/or bilateral oophorectomy men document azoospermia ) eligible without require use contraception . Acceptable documentation sterilization , azoospermia , menopause specify : Written oral documentation communicate clinician clinician 's staff one following : Physician report/letter Operative report source documentation subject record successful vasectomy Discharge summary Laboratory report azoospermia Follicle stimulate hormone measurement elevate menopausal range</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>